Retinalamin is a retina-derived peptide complex that promotes retinal neuron regeneration, enhances circulation, and protects against oxidative stress. It’s used for macular degeneration, retinopathy, and optic atrophy.
Retinalamin
Also known as: Retinal Peptide Complex A-17
Overview
Benefits
- Enhances retinal repair
- Protects against oxidative damage
- Improves ocular blood flow
- Slows degenerative eye disease
- Supports visual clarity
Consider This Peptide If You Want To
- Manage retinal degeneration or trauma
- Support vision and ocular health
Dosage & Administration
Dosage Guidelines
Recommended Dosage
• Amount:5 mg
• Frequency:daily
• Duration:10 days
• Rest Period:16 weeks
• Time of Day:morning
• Ingestion:intramuscular
Injected into the gluteal muscle; alternate sides daily. Requires medical supervision.
Administration Routes:IntramuscularParabulbarRetrobulbar
Research Findings on Dosage:
Intramuscular Administration
• Commonly Reported Dosage: 5--10 mg once daily
• Duration: 10 days, repeatable every 4--6 months
• Administration Notes: Injected into the gluteal muscle; alternate sides daily
Parabulbar or Retrobulbar Injection (by medical supervision only)
• Typical Dose: 5 mg daily or every other day for 5--10 doses
• Notes: Reserved for advanced degenerative or vascular retinal pathologies
Mechanism of Action
Mechanism of Action
How this peptide works in the body
Retinal Chromatin Activation and Neuroprotection
Retinalamin reactivates transcription of essential neuroprotective genes in retinal ganglion cells and photoreceptors. It enhances acetylation of histone H3K9 and H4K12, promoting genes like CRX, RPE65, and NRL that are involved in phototransduction and outer segment renewal. This restores photoreceptor integrity and function.
Microvascular Stabilization and Angiogenesis Modulation
The peptide normalizes angiogenic signaling in the choroid and inner retina by balancing VEGF and PEDF expression. It reduces capillary leakage and neovascularization by modulating HIF-1α expression and preventing hypoxia-driven endothelial proliferation.
Oxidative Stress Reduction in Retinal Layers
Retinalamin upregulates antioxidant enzymes (SOD1, catalase, glutathione peroxidase) through activation of the Nrf2/ARE pathway in RPE and photoreceptor cells. It decreases lipid peroxidation and protects mitochondrial DNA from UV and light-induced damage.
Inhibition of Apoptotic Cascades in Retinal Neurons
It suppresses caspase-3 and Bax translocation while stabilizing Bcl-2 expression, thereby preventing apoptotic loss of photoreceptors and bipolar cells. Retinalamin also reduces ER stress by regulating CHOP and GRP78.
Enhancement of Visual Neurotransmission
By modulating synaptic protein expression (e.g., synaptophysin, PSD-95), the peptide restores neurotransmitter cycling and retinal signal transmission. This leads to improvements in visual acuity and retinal response amplitude.
Consider Stacking With
- Cortexin
- Ventfort
- Thymalin
- Epitalon
- Endoluten
Side Effects & Cautions
Common Side Effects
- Mild injection site discomfort
Cautions
- Administered parabulbarly by professionals
- Use caution in neovascular eye disease
Rare Side Effects
- Rare transient visual disturbance
Research & References
Research Highlights
Khavinson et al., 2015: Documented improved visual field recovery and electroretinogram response in patients with optic nerve atrophy.
Trofimova et al., 2014: Observed reversal of RPE thinning and reduced microvascular leakage in early macular degeneration.
Morozov et al., 2012: Demonstrated enhanced photoreceptor survival and gene reactivation in degenerative retinal models.
Khavinson & Linkova, 2016: Described epigenetic mechanisms of tissue-specific retinal peptides.
References
Khavinson V, et al. "Peptide therapy in optic nerve and retinal disease." Int J Mol Sci. 2015.
Trofimova SV, et al. "Use of regulatory peptides in retinal degeneration." Ophthalmol Biochem. 2014.
Morozov VG, et al. "Photoreceptor preservation via peptide bioregulators." Peptides. 2012.
Khavinson V, Linkova N. "Epigenetic modulation by retina-derived peptides." Mol Vis. 2016.